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Scaffolda b s t r a c t
Antibodies, which can recognize a plethora of possible antigens, have been considered as a paradigm
of protein engineering performed by nature itself. Lipocalins constitute a distinct family of proteins
with functions in ligand binding and transport that occur in many organisms, including man. Like
antibodies, lipocalins exhibit a structurally conserved framework – a b-barrel with an attached a-
helix – which supports four structurally hypervariable loops forming a cup-shaped binding site.
Thus, lipocalins offer an ideal platform for protein engineering to generate novel binding reagents.
Using recombinant/synthetic DNA technology and methods of combinatorial library selection,
‘Anticalins’ with prescribed target speciﬁcities can be easily generated. Anticalins with picomolar
afﬁnities have been developed for three classes of ligands having relevance in basic research and/
or medical application: small molecules, peptides, and proteinaceous signalling molecules as well
as cell surface receptors. Anticalins derived from human lipocalins have already reached the clinical
trial stage. Due to their very small size and simple composition of a single polypeptide chain, which
also facilitates the construction of bifunctional fusion proteins, Anticalins promise beneﬁts as a next
class of biopharmaceuticals.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Lipocalins as an alternative protein scaffold to
immunoglobulins
Antibodies, also known as immunoglobulins (Igs), represent a
widely accepted class of biochemical reagents. Due to their speciﬁc
and tight binding properties against almost all kinds of substances
(antigens and haptens) they have provided valuable tools for bio-
medical research and therapy for more than a century. Antibodies
were initially made amenable to protein engineering by the devel-
opment of methods for the production of functional Ig fragments in
Escherichia coli [1,2], which laid the foundation of current antibody
technology. Today, more than 25 Ig-based products are approved
for therapeutic use, mainly for the treatment of cancer and autoim-
mune disorders [3].
While naked monoclonal antibodies (MAbs) – and also their
conjugates with radioactive payloads or probes – have already
been in use for cancer treatment or in vivo imaging for several
years, this toolbox was recently expanded by the development of
more specialized formats such as bispeciﬁc MAbs or antibody-drug
conjugates (ADCs) [4]. To reduce immunogenicity and maintainimmunological effector functions, MAbs of murine origin have
been replaced by chimeric, humanized or even fully human for-
mats in almost all therapeutic settings. However, owing to their
relatively large molecular size of about 150 kDa, their nature as
multiple-disulﬁde-crosslinked and glycosylated proteins and their
composition of in total four polypeptide chains (two heavy and two
light chains), whole Igs can be efﬁciently produced only by eukary-
otic cells.
From a structural point of view, the antigen-binding site of an
antibody is formed by altogether six hypervariable loop regions
(also known as complementarity determining regions, CDRs), three
in each of the two variable domains (Fig. 1). The CDRs are displayed
on a conserved framework comprising a sandwich of disulﬁde-
linked b-sheets which form the typical Ig fold [5]. The high amino
acid sequence variability within the six CDRs accounts for the vast
number of possible antigen speciﬁcities and genetically arises from
somatic recombination of an inherited set of gene cassettes in con-
junction with hypermutation.
Despite the success of antibodies in many applications, the
molecular format of Igs is also associated with some practical dis-
advantages from a protein engineering perspective and with regard
to clinical use: (i) because of the complex architecture the produc-
tion of full-length Igs is expensive and laborious as complicated
mammalian expression systems are usually necessary; (ii)
immunological effector functions mediated by the Fc region can
Fig. 1. Comparison of Ig Fv fragments (left) with Anticalins (right). Both comprise a structurally conserved framework (grey) supporting a set of hypervariable loops (colored)
that account for target recognition. Fv moieties from six crystal structures of Igs directed against haptens (PDB codes 3QCU and 3TV3), peptides (PDB codes 3UJJ and 3UJI) or
protein antigens (PDB codes 3TCL and 4JDV) were superimposed on the basis of their framework regions. The wild-type lipocalin 2 (Lcn2), which originally binds the metal-
chelate FeIIIenterobactin [19], was superimposed with ﬁve Lcn2-derived Anticalins (see Fig. 2) recognizing a hapten, two peptides and two protein targets by using a set of 58
Ca positions that are structurally conserved in the b-barrel framework [12].
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tions; (iii) poor tissue penetration due to the large molecular size
hampers successful treatment of solid tumors; (iv) the long circu-
lation in blood resulting from both the large size and FcRn-medi-
ated endosomal recycling is unfavorable for in vivo imaging and
also for therapeutic applications that require prompt adjustment
of dosing.
While some of these disadvantages may be overcome by using
recombinant Ig fragments or so-called single domain antibodies
from cameloids or sharks [6–8], these formats still come with their
own peculiarities, such as the necessary chain pairing of Fab, the
oligomerization tendency of scFv and the bisected combining site
(comprising merely three CDRs) of the single domain antibodies.
Given these constraints, the idea of mimicking the highly speciﬁc
antigen-binding site of Igs by using a different protein scaffold that
exhibits structurally variable loops appeared attractive. In this re-
gard, the lipocalin protein family with its simple molecular archi-
tecture, small size and beneﬁcial production characteristics
offered the potential to engineer novel highly speciﬁc protein re-
agents by using combinatorial mutagenesis and molecular selec-
tion methods.
The lipocalins represent a diverse family of robust extracellular
proteins, each comprising a single polypeptide chain of 150–190
amino acids. They are abundant in humans, plants, vertebrates, in-
sects, bacteria as well as other genera [9]. So far, twelve different
lipocalins have been identiﬁed in man [10], where they are se-
creted into the blood or tissue ﬂuids and serve for the transport
or sequestration of typically hydrophobic and/or chemically sensi-
tive compounds. One well-characterized physiological ligand is the
poorly soluble and oxidation-prone vitamin A, which is carried by
the retinol-binding protein (RBP) from the liver, as the site of its
storage, to different target tissues.
Despite surprisingly low mutual sequence homology [11], lipo-
calins share a conserved three-dimensional fold that is dominated
by eight antiparallel b-strands which form a circularly closed, cup-
shaped b-barrel core with a C-terminal a-helix attached to its site
(Fig. 1). At the open end of the cup (greek: calyx) the b-strands are
connected in a pair-wise manner by four structurally variable loops
that, together with adjoining residues within the b-barrel, form the
natural ligand-binding site. Thus, the structural composition of
lipocalins with their b-barrel framework which supports an ex-
posed set of loops is remarkably similar to the format of the pairedvariable domains carrying the antigen-binding site of antibodies
[12].
However, there are three notable differences between lipocalins
and Igs. First, lipocalins are not diversiﬁed by somatic gene recom-
bination/hypermutation mechanisms as provided for antibodies by
the immune system. Second, lipocalins exhibit four hypervariable
loops instead of six for intact Igs (or three for single domain anti-
bodies); thus, a simple loop grafting from Igs to lipocalins, as per-
formed during antibody humanization, for example [13], is not
possible. Third, compared to the combining site of Igs, which usu-
ally forms a rather ﬂat interface, lipocalins possess a characteristic
deep ligand pocket and, consequently, they are particularly suit-
able for the tight binding of small, hapten-type compounds or pep-
tides, beside larger macromolecular antigens (Fig. 2).
2. Engineered lipocalins for recognition of prescribedmolecular
targets
Based on the conceptual similarity with Igs described above, we
set out to generate lipocalins with novel ligand-binding functions,
dubbed Anticalins [12,14], using the methods of combinatorial pro-
tein engineering, i.e. targeted random mutagenesis of the variable
loop regions in combination with powerful library selection tech-
niques such as phage display [15]. To this end, four natural lipocalin
scaffolds appeared of special interest on the basis of their known
three-dimensional structures: the bilin-binding protein (BBP) from
the butterﬂy Pieris brassicae [16], the human apolipoprotein D [17],
the human lipocalin 1 (Lcn1), also known as tear lipocalin (Tlc) [18],
and the human lipocalin 2 (Lcn2), also known as neutrophil gelatin-
ase-associated lipocalin (NGAL) or siderocalin [19].
BBP is a blue pigment protein that protects insects from
oxidative stress, which was chosen as a model lipocalin during in-
ital studies to engineer binding sites with novel target speciﬁcities.
Randomization of 16 deﬁned amino acid positions within the four
hypervariable loops – as well as adjoining parts of the
b-strands – was well tolerated by this scaffold and resulted in
the generation of the ﬁrst Anticalins with high afﬁnities for the
dye ﬂuorescein [14], the plant steroid digoxigenin [20] and a
phthalic ester plasticiser [21], all with afﬁnities in the low
nanomolar range. These original ﬁndings demonstrated the high
tolerance of the lipocalin scaffold for artiﬁcially introduced side
chain substitutions on a wider scale and reconﬁrmed our notion
Fig. 2. Crystal structures of ﬁve Anticalins based on the human Lcn2 scaffold with speciﬁcities for different types of targets (blue). Anticalins are depicted in complex with the
peptide ligands Ab40 (orange; to be published) and hepcidin (yellow; to be published), the small hapten-like molecule YIIIDTPA (green; PDB code 4IAX) and with the two
protein targets ED-B (magenta; PDB code 4GH7) and CTLA-4 (red; PDB code 3BX7).
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lins and the antigen-binding site of antibodies. In case of the digox-
igenin- and ﬂuorescein-speciﬁc Anticalins the mechanism of
ligand-binding to the engineered lipocalins was investigated in
greater detail via site-directed mutagenesis and crystal structure
analysis [22–24].
Consequently, the next step was the design of Anticalins based
on human lipocalins, in particular Lcn1 and Lcn2, to ensure high
tolerability to patients upon medical application [15]. Such Antica-
lins are generated via combinatorial protein engineering in a four
step process that in principle resembles the humoral immune re-
sponse against an antigen:
First, a genetic library with speciﬁcally randomized amino acid
positions is prepared. As the number of side chains that form the
ligand-binding site in the lipocalin scaffold, which lies in the range
between 30 and 50 residues, is far larger than the combinatorial se-
quence space that can be physically realized [25], the careful
choice of the most relevant set of 16–20 positions plays a crucial
role (Fig. 3). Several Anticalin libraries have been constructed up
to now, for example on the basis of the BBP, Lcn1, Lcn2 and some
other human lipocalin scaffolds. In the case of Lcn2, the library de-
sign has been subject to iterative optimization [26] involving suc-
cessive X-ray structural analyses of selected Anticalins as described
further below.
Second, lipocalin variants with speciﬁc ligand-binding proper-
ties are then selected from the naïve random library. So far, the
phage display technique has been successfully applied to isolate
Anticalins with low nanomolar and sometimes even picomolar dis-
sociation constants from combinatorial lipocalin libraries with
complexities of 4  108 [14] to 2  1010 [26]. While phage displayselection via biopanning usually only leads to enrichment of a pop-
ulation of protein variants with some binding function, high
throughput screening (HTS) and ELISA techniques subsequently al-
low the identiﬁcation of individual Anticalins having speciﬁc bind-
ing activity, which is further conﬁrmed by including dummy
targets as negative controls in parallel experiments [15].
Resulting candidate Anticalins are then expressed at the shake
ﬂask scale, puriﬁed by afﬁnity chromatography and analyzed (i)
for monomeric solution properties via size exclusion chromatogra-
phy (SEC) and (ii) for target afﬁnity using real-time surface plas-
mon resonance (SPR) spectroscopy or similar techniques [26].
Recently, Anticalins have also been made amenable to bacterial
surface display [27]. In this case, the library of mutated lipocalins
is presented on the outer membrane of the Gram-negative bacte-
rium E. coli fused to the integral membrane domain of a bacterial
autotransporter protein. The lipocalin scaffold appears particularly
suitable for this approach, which has been unsuccessful with anti-
body fragments, probably due to their delicate disulﬁde bond pat-
tern. This method allows the rapid and convenient selection of
cognate Anticalins via ﬂuorescence-activated cell sorting (FACS)
after incubation of the bacterial library with the ﬂuorescently la-
beled target molecule.
Finally, once an Anticalin with speciﬁc molecular recognition
properties has been selected, its initial properties can be further
improved in a process called in vitro afﬁnity maturation, which
again has been inspired by the mechanisms of humoral immune
response. To this end, the central coding region of the engineered
lipocalin, encompassing all four hypervariable loops, is subjected
to error-prone mutagenesis, typically involving the polymerase
chain reaction (PCR), and the resulting focused library is subjected
Fig. 3. Graph illustrating the probability of selecting a binding protein against any target from a naïve (unbiased) random library depending on the number N of variegated
residues in the chosen protein scaffold. For theoretical reasons, this probability must approach zero both for N = 0 and for N = Nmax (i.e. the total number of residues in the
protein scaffold) and, consequently, there has to be a of maximum in between (at Nopt). This maximum is the result of two opposing effects: with decreasing number of
randomized residues the likelihood of creating a sufﬁciently large matching interface with the target diminishes while with increasing N the physical coverage of the library
rapidly declines and sampling becomes vastly incomplete. In practice, just a tiny fraction of all combinatorial variants can be covered – up to around 1011 for phage display
and up to 1013 for ribosome display, corresponding to merely about 7 fully randomized positions (a value clearly too small to generate a sufﬁciently large interface with
complementary shape for most targets). The question remains how broad (blue line) or narrow (red lines) this probability distribution is and where Nopt occurs. Naturally, the
probability of selecting a binding protein rises with increasing complexity of the physical library (vertical arrow and dashed line). From experimental experience with the
lipocalin scaffold it appears that the maximum is narrow and lies in the region N  16–20. Under these constraints, an optimal choice of side chains to be randomized (red)
among the approximately 50 residues in total that shape the entire ligand-binding site (blue) has to be made (see inset) [26].
216 A. Richter et al. / FEBS Letters 588 (2014) 213–218to another selection against the same target, this time under more
stringent conditions [28]. Selection cannot only be driven for im-
proved target afﬁnity or slower dissociation rate but also towards
generic properties such as higher protein stability – e.g. via selec-
tion at elevated temperature or in the presence of denaturants –
or reduced aggregation. These optimization procedures typically
involve iterative cycles, which may be complemented by positional
saturation mutagenesis once sensitive residues have been identi-
ﬁed in the course of an error-prone PCR approach or, possibly, after
elucidation of the three-dimensional structure, thus providing a
basis for rational protein engineering [29].
3. Selection of Anticalins against targets of biomedical
relevance
During the last years, Anticalins directed against various differ-
ent target formats, that is proteins, peptides and small molecules,
have been developed (Fig. 2). Human Lcn2 has emerged as a partic-
ularly versatile scaffold to generate Anticalins with exquisite bind-
ing activities and superior biochemical properties regarding
protein stability and strictly monomeric behavior. Using an Lcn2-
based library designed for the binding of small, hapten-like mole-
cules, Anticalins speciﬁcally recognizing a metal–chelate complex
comprising a lanthanide ion, e.g. YIII, and a derivative of diethyl-
enetriamine pentaacetic acid (DTPA) were selected [28]. A recently
published version of this MeDTPA-speciﬁc Anticalin that has been
subject to biochemical optimization [29] is now under pre-clinical
investigation for in vivo pretargeting radioimmuno therapy (RIT)
and diagnostics. Another Lcn2-based random library was con-
structed to generate Anticalins capable of tightly complexing volu-
minous, antigen-type protein targets and successfully applied to
the extracellular domain of cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4, CD152) as a disease-relevant target [30]. Due
to its function as a negative regulatory T-cell co-receptor, the
Anticalins with subnanomolar afﬁnities, obtained by in vitro afﬁn-
ity maturation, had potent blocking activity and showed an immu-
nostimulatory effect on the T-cell response in an animal model of
infectious disease [31].Based on these experimental results and on a series of X-ray
structures of selected Anticalins in complex with their target mol-
ecules (cf. Fig. 2), a third generation Lcn2-based random library
was recently described [26]. This library combines a presumably
optimal distribution of randomized amino acid positions within
the binding site of the lipocalin scaffold, amenable to interaction
with target molecules of diverse size and shape, with a trinucleo-
tide-based DNA synthesis technique that avoids stop codons and
Cys substitutions as well as codon bias due to the degenerated ge-
netic code.
Using this ‘New’ library, Anticalins that speciﬁcally recognize a
disease-relevant splice variant of the extracellular matrix protein
ﬁbronectin (Fn), exhibiting the so-called extra-domain B (ED-B),
were developed with afﬁnities in the single-digit nanomolar range
[26]. Since ED-B-positive Fn is speciﬁcally expressed during tumor
angiogenesis, it has emerged as a promising marker for various
cancers and constitutes a validated target for in vivo imaging
[32]. These Anticalins exhibit speciﬁc staining of ED-B positive cells
in immunoﬂuorescence microscopy and of human glioma neovas-
culature in immunohistochemistry. Hence, owing to their high sta-
bility and monomeric biochemical behavior Anticalins show
promise for applications in oncology.
A series of other Anticalins have also been selected from this
Lcn2-based library which potentially address a broad spectrum of
human diseases by recognizing well known targets such as
VEGFR-3 and Hsp70 in cancer, the Ab peptide in Alzheimer’s
disease and hepcidin, a negative regulator of iron homeostasis, in
anemia [33]. The development of Anticalins against the hepcidin
peptide has been funded by the European Commission in frame
of the EUROCALIN Consortium to promote clinical investigation
(http://www.eurocalin-fp7.eu).
Apart from Anticalins derived from the Lcn2 scaffold, other
members of the lipocalin family have been successfully applied
to generate highly speciﬁc and functionally active Anticalins. The
human Lcn1/Tlc scaffold served to develop a drug candidate for
the treatment of solid cancers that effectively blocks the vascular
endothelial growth factor (VEGF-A) [34]. This Anticalin, dubbed
Angiocal (PRS-050), has been investigated as inhibitor of tumor
Fig. 4. Potential of Anticalins in the area of medical diagnostics and therapy. Engineered lipocalins exhibit key features that enable versatile and wide-spread application in
biopharmaceutical research and industry. In general, Anticalins are easy to manufacture in various established expression systems, they show exquisite afﬁnity and speciﬁcity
towards all disease-relevant types of targets, and they offer a broad spectrum of in vivo applications due to ﬂexible formatting as bispeciﬁcs as well as tunable
pharmacokinetics.
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and high tolerability as well as lack of immunogenicity [35]. Based
on the promising data from this repeated dose escalating study,
Angiocal is recommended to enter clinical Phase II (http://
www.pieris-ag.com). Recently, another Anticalin based on the
Lcn1/Tlc scaffold that is directed against the hepatocyte growth
factor receptor (HGFR; c-Met proto-oncogene) has been described
to act as a highly potent and speciﬁc MET antagonist with both li-
gand-dependent and ligand-independent activity [36].
The BBP lipocalin scaffold (discussed above) has been investi-
gated for biomedical uses, too. The ﬂuorescein-speciﬁc Anticalin
FluA was applied, after genetic fusion to an Ig Fv fragment that rec-
ognized the Fn extra-domain A as angiogenesis marker, to pretar-
geted payload delivery in a mouse tumor xenograft model [37].
Furthermore, the afﬁnity-improved digoxigenin-binding Anticalin
(DigiCal) showed promising results in a rat study as antidote for
the treatment of digitalis intoxication [38]. Recently, a new BBP-
derived Anticalin was selected via ribosome display to recognize
the sex hormone estradiol [39].4. Present and future trends of the Anticalin technology
Anticalins constitute a promising class of engineered therapeu-
tic proteins that exhibit key features of a potent, safe and economic
drug (Fig. 4). Beside fundamental prerequisites for biopharmaceu-
tical development, including high target afﬁnity (nano- to picomo-
lar range) and exquisite speciﬁcity, pronounced protein stability
and low immunogenicity as well as facile manufacturing and puri-
ﬁcation, they offer deep tissue penetration due to their small size
of just about 20 kDa. To ensure broad therapeutic applicability,
several established techniques are available to prolong the intrin-
sically short plasma half-life of Anticalins, not only by chemical
PEGylation but also via fusion to an albumin-binding domain
[20] or by applying PASylation [40].Due to their monovalent binding function the risk of intermo-
lecular crosslinking of targets or clustering of cell surface receptors
is low, which provides an advantage for the design of potent antag-
onists. Nevertheless, if required, bivalency can be accomplished by
genetic fusion of an Anticalin via its ﬂexible N- or C-terminus
either to another Anticalin, yielding a so-called Duocalin [41], or
to an Ig fragment or a different kind of binding protein. For biomo-
lecular imaging and detection, Anticalins can be genetically fused
to a ﬂuorescent protein or chemically coupled to a dye or a radio-
metal chelator. Generally, Anticalins show promise for tumor ther-
apy [33], both as antagonists of growth factors (such as VEGF-A),
receptors (such as HGFR) or of immunoregulatory molecules (such
as CTLA-4) and, if directed against a tumor cell surface marker, as
fusion proteins or conjugates with toxin payloads of various kind.
In summary, Anticalins have potential as next-generation biol-
ogics for the treatment and diagnosis of human diseases and as re-
search reagents that may complement and even supersede
conventional antibodies in many areas.
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